Drug Profile
BI 137882
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antiasthmatics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Chronic obstructive pulmonary disease
Most Recent Events
- 27 Feb 2013 Boehringer Ingelheim terminates its phase I trial in healthy volunteers in Germany (NCT01348165)
- 23 Aug 2011 Suspended - Phase-I for Chronic obstructive pulmonary disease in Germany (PO)
- 31 May 2011 Phase-I clinical trials in Chronic obstructive pulmonary disease (in volunteers) in Germany (PO)